Provided by Tiger Trade Technology Pte. Ltd.

Immix Biopharma, Inc.

8.15
-0.5700-6.54%
Post-market: 8.310.1600+1.96%17:08 EDT
Volume:750.44K
Turnover:6.27M
Market Cap:431.58M
PE:-10.48
High:9.19
Open:8.97
Low:8.00
Close:8.72
52wk High:11.61
52wk Low:1.34
Shares:52.96M
Float Shares:41.44M
Volume Ratio:0.71
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7776
EPS(LYR):-0.7641
ROE:-55.00%
ROA:-29.30%
PB:4.60
PE(LYR):-10.67

Loading ...

Jul 26, 2024

Major Issues Report

Form 8-K - Current report
Jul 22, 2024

Major Issues Report

Form 8-K - Current report
Jul 22, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Jun 14, 2024

Major Issues Report

Form 8-K - Current report
May 20, 2024

Major Issues Report

Form 8-K - Current report
May 09, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mar 29, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 17, 2024

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Feb 07, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 06, 2024

Major Issues Report

Form 8-K - Current report
Feb 05, 2024

Major Issues Report

Form 8-K - Current report
Nov 10, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Sep 26, 2023

Correspondence

Form CORRESP - Correspondence
Aug 30, 2023

Beneficial Ownership Change

Form SC 13D - General statement of acquisition of beneficial ownership
Aug 23, 2023

Major Issues Report

Form 8-K - Current report
Aug 11, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 15, 2023

Major Issues Report

Form 8-K - Current report
Jun 14, 2023

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Jun 08, 2023

Major Issues Report

Form 8-K - Current report
May 12, 2023

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]